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INTRODUCTION
Gastric cancer (GC) is the third leading cause of cancer-related 
deaths and is the most common gastrointestinal malignancy 
in East Asia, Eastern Europe, and parts of Central and South 
America.1,2 Epigenetic and genetic alterations account for a 
large proportion of carcinogenesis in various organs, including 
GC.3-5 Accumulation of multiple genetic alterations or epigen-
etic changes has been shown to be associated with dysregula-
tion of oncogenes and tumor suppressor genes in GC.6,7
Alteration of the Wnt/β-catenin signaling induces the accu-
mulation and nuclear translocation of β-catenin, and is close-
ly associated with the development and progression of GCs.8 
The Wnt/β-catenin signaling components, including the effec-
tors and negative regulators, are often altered by epigenetic man-
ners, including DNA methylation and histone modifications in 
various tumors. Meanwhile, research has shown that negative 
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regulators of Wnt/β-catenin signaling are important for tumor 
suppression: CXXC4 (CXXC finger protein 4), a negative regu-
lator of Wnt/β-catenin signaling, is reduced by enhancer of 
zeste homolog 2 (EZH2) in GC8,9 EZH2 plays an important 
role in epigenetic regulation of the human genome and is 
known to be associated with the development of various can-
cers.10 Growing evidence has also indicated that Wnt/β-catenin 
signaling components are regulated by not only long non-cod-
ing RNAs (lncRNAs) but also other noncoding classes.11-15
LncRNAs, non-coding RNA transcripts, contain more than 
200 nucleotides that lack protein coding potential.16-18 LncRNAs 
have been linked to a wide range of epigenetic alterations in 
various cancers, including chromatin-related changes, DNA 
methylation, and splicing control.17,19-24 Numerous lncRNAs 
have been found to contribute to cancer cell functions through 
silencing of tumor suppressors via interaction with EZH2.10 A 
significant number of lncRNAs have been reported to be in-
volved in cancer development by inhibiting tumor suppressor 
genes through binding with EZH2.10,25,26 We recently reported 
that highly expressed lncRNA12 in esophageal squamous cell 
carcinoma (HERES) regulate Wnt/β-catenin signaling via in-
teraction with EZH2.12 
We previously reported that LUCAT1 promotes tumorigene-
sis by controlling the ubiquitination and stability of DNA meth-
yltransferase 1 (DNMT1) in esophageal squamous cell carci-
noma (ESCC).27 LUCAT1 activated DNMT1, a major DNA 
methylation protein, to repress the expression of tumor sup-
pressor genes known to be involved in ESCC carcinogenesis. 
Since the publication of our report, LUCAT1 has been report-
ed to be involved in the development of clear cell renal cell car-
cinoma, non-small lung cancer, glioma, osteosarcoma, and 
colorectal cancer.27-33
In this study, we investigated the functions and molecular 
mechanisms of LUCAT1 in the carcinogenesis of GC. The acti-
vation of EZH2 induced activation of the Wnt/β-catenin path-
way by repressing CXXC4 expression in GC.34 We also explored 
the interactions of LUCAT1 and EZH2, as well as regulatory 
networks of Wnt/β-catenin signaling,8 with CXXC4 and SFRP2 
in GC.
MATERIALS AND METHODS
Patients and tissue samples
In total, 100 GC tissue and paired adjacent gastric tissue sam-
ples were obtained from patients who underwent surgical re-
section for GC at Severance Hospital, Yonsei University Col-
lege of Medicine. All samples were frozen in liquid nitrogen 
immediately after resection and stored at -80°C. All tissue sam-
ples were obtained after receiving written informed consent 
from patients according to the Declaration of Helsinki, and this 
study was approved by Institutional Review Board of the Yon-
sei University College of Medicine (# 4-2011-0753). 
Cell lines and cell culture
GC cell lines (AGS, MKN28, MKN45, MKN74, KATOIII) and 
the normal gastric cell line (GES1) were purchased from the 
Korean Cell Line Bank (KCLB, SNU, Seoul, Korea) and the 
American Type Culture Collection (ATCC, Rockville, MD, USA). 
The cells were cultured in RPMI-1640 medium or DMEM me-
dium (Thermo Scientific, Rockford, IL, USA) supplemented 
with 10% fetal bovine serum and 1% penicillin/streptomycin 
(Thermo Scientific). All cells were maintained in a humidified 
atmosphere of 5% CO2 at 37°C. 
Small interfering RNA (siRNA) transfection
For transfection, AGS, MKN28, and MKN74 cells (3×105) were 
seeded in 6-well plates and incubated in a 37°C incubator. Af-
ter 24 hours, the cells were treated with targeted siRNA (Ln-
cRNA LUCAT1, 50 μM) and RNAi negative control (50 μM, 
siCT; Invitrogen, Carlsbad, CA, USA) with Lipofectamine 
2000 reagent (Invitrogen) following the manufacturer’s pro-
tocol. For double knock-out transfection, the LUCAT1 and EZH2 
siRNA target sequences were as follows: siLUCAT1_1 sense, 
CAGAAGAUUCAGAAGAUAAGGAU and antisense, AUC-
CUUAUCUUCUGACAUCUUCUG; siLUCAT1_2 sense, 
AGGCCUUGCUCAGUGUCACACAU and antisense, AAU-
GUGUGACACUGAGCAAGGCCU. siEZH2 sense, UUCAUG-
CAACACCCAACACU; siEZH2 antisense GAGAGCAGCAG-
CAAACUCCU.
Construction of LUCAT1 overexpression plasmid 
The LUCAT1 cDNA was amplified by a PCR system (Roche Ap-
plied Science, Penzberg, Upper Bavaria, Germany). To insert 
the cDNA into the pcDNA3.1 (+) expression vector, LUCAT1_
NHel_F (acccaagctggctagc CAATGCCCAGACCTCCAG) and 
LUCAT1_Xbal_R (aaacgggccctctaga TTGACTGCAAGAGCTT-
GAAG) were used as cloning primers. The pcDNA3.1 (+) ex-
pression vector was obtained from Addgene. AGS cells were 
transfected with 1 μg of pcDNA3.1-LUCAT1 for 24 hours using 
Lipofectamine 2000 (Invitrogen). Transfection was conducted 
with 1 μg of pcDNA3.1-LUCAT1 using Lipofectamine 2000 for 
24 hours.
Total RNA extraction and quantitative real-time 
reverse transcription polymerase chain reaction
Total RNA was obtained from GC tissues and cell lines using 
TRIzol reagent (Invitrogen). RNA was quantified using Nano-
drop (ND-100; Nanodrop Technologies Inc., Wilmington, DE, 
USA). Purity was determined at a 260/280 nm ratio, and prod-
ucts were loaded on 1% agarose gel. For cDNA synthesis, 2.0 
μg of total RNA was reverse transcribed with SuperscriptTMII 
(Invitrogen) following the manufacturer’s protocol. Relative 
levels of LUCAT1 were measured by real-time PCR using iQ 
SYBR Green Supermix (Applied Biosystems Inc., Carlsbad, 
CA, USA). The Ct value of the sample was normalized to U6 or 
GAPDH expression, and 2−ΔΔCt values were calculated. Prim-
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ers used for qRT-PCR are shown in Supplementary Table 1 
(only online).
Cell proliferation analysis
GC cells were transfected with 50 μM siLUCAT1s or siCT from 
0 to 72 hours. Cell proliferation was performed by CellTiter 96® 
AQueous One Solution Cell Proliferation Assay (MTS assay; 
Promega, Madison, WI, USA) in 96-well culture plates in time-
dependent conditions. The plate was allowed to react with 
MTS reagent for 1 hour in the dark, and products of the reac-
tion were assessed on a spectrophotometric plate reader set 
at 490 nm (Multiskan Microplate Photometer; Thermo Scien-
tific). For rescue experiments, cells were transfected with pcD-
NA-LUCAT1 48 hours after siRNA transfection, and cell prolif-
eration was conducted.
Apoptosis analysis
AGS, MKN28, and MKN74 cells were transfected with LUCAT1 
siRNA or siCT, and the cell pellet was isolated after 48 hours. 
The cell pellet was resuspended in 1 × binding buffer (BD Bio-
science, San Jose, CA, USA) and phosphate-buffered saline 
(PBS). Cells were stained with propidium iodide and fluores-
cein isothiocyanate (FITC) annexin V using a FITC-Annexin V 
kits (BD Bioscience). For analysis by flow cytometry using a 
FACS verse instrument (BD Biosciences), the stained cells 
were incubated for 15 minutes. Data were analyzed using Flow 
Jo software (Treestar, Ashland, OR, USA). Three experiments 
were conducted for each assay. For apoptosis analysis, the 
same three GC cell lines were washed with PBS and resus-
pended in 1× binding buffer (BD Biosciences). FITC Annexin 
V and propidium iodide staining was conducted with the FITC 
Annexin V detection kit (BD Biosciences) according to the man-
ufacturer’s protocol. The ratio of percentage apoptosis was 
measured by flow cytometry (BD Biosciences).
Scratch wound healing assay and invasion assay
AGS, MKN28, and MKN74 cells were seeded in 6-well cul-
tured plates transfected with siLUCAT1s or siCT. When the 
cells achieved approximately 60–80% confluency, the bottom 
of the well was scratched equally using a P-20 tip. The width of 
scratched cells was measured at 0 and 24 h for AGS and 
MKN28 cells at 0 and 36 h for MKN74 cells by microscopy. For 
invasion assay, two different siLUCAT1s were transfected into 
AGS, MKN28, and MKN74 cells, and cells were then reseeded 
in Matrigel Invasion Chambers (BD Biosciences) in a 24-well 
culture plate. After 24 h or 36 h, non-invading cells within the 
insert chamber were removed, and the upper layer of the 
trans-well was briefly wiped with a cotton swab. The mem-
brane of the bottom part of the upper chamber was fixed with 
5% acetaldehyde buffer and stained with Crystal violet solu-
tion. The invading cells on the membrane were counted un-
der a bright-field microscope.
Soft agar colony formation assay
To analyze tumorigenicity in vitro, base and top layers of aga-
rose were coated with cells in 96-well plates using CytoSelectTM 
96-Well Cell Transformation Assay (CELL BIOLABS, INC, San 
Diego, CA, USA). As a base layer, 1.5 mL of 2X DMEM contain-
ing 1% agarose was poured into each well. After 1 hour of so-
lidification, transfected cells were resuspended in 2X DMEM 
containing 0.7% agarose as a top layer and then maintained in 
an incubator at 37°C for 2–3 weeks. After daily observation, col-
onies were captured under bright field microscopy.
Western blot
Cells transfected with siLUCATs or siCT were lysed in 1X RIPA 
buffer (Cell Signaling Technology, Danvers, MA, USA) con-
taining protease inhibitor. Isolated proteins were loaded by 
8–15% SDS–polyacrylamide gel electrophoresis and trans-
ferred to a polyvinylidene difluoride membrane (GE Health-
care, Piscataway, NJ, USA). The membrane was blocked for 1 
hour at room temperature in tris–phosphate buffer containing 
0.1% Tween 20 with 5% bovine serum albumin (BD Biosci-
ences) and then incubated with primary antibodies at 4°C in a 
cold room overnight. The following primary antibodies were 
used for Western blot analysis: epithelial marker E-cadherin 
(1:1000, BD Biosciences); mesenchymal marker N-cadherin 
(1:1000, BD Biosciences), Vimentin (1:200, Santa Cruz Bio-
technology, Dallas, TX, USA, sc-373717), ZEB1 (1:1000, Cell 
Signaling Technology, #3396S), Snail (1:1000, Cell Signaling 
Technology, #3879S), PARP (1:1000, Cell Signaling Technology, 
#9542), Bcl-xl (1:1000, Cell Signaling Technology, #2764), Bax 
(1:1000, Santa Cruz Biotechnology, sc-493), CXXC4 (1:500, Ab-
cam, Cambridge, UK, ab105400), EZH2 (1:1000, Cell Signaling 
Technology, #5246S), WNT1 (1:500, Abcam, ab15251), SFRP2 
(1:200, Abcam, ab86379), and β-actin (1:5000, Bioworld Tech-
nology, Louis Park, MN, USA, AP0060). Signals were devel-
oped in ECL solution (GenDEPOT, Barker, TX, USA) and ex-
posed to an Image Quant LAS 4000 bio-molecular imager for 
10 seconds to 6 minutes.
RNA immunoprecipitation (RIP)
Cells were lysed with immunoprecipitation buffer (Thermo 
Fisher Scientific, Middlesex County, MA, USA) and resuspend-
ed in RIP buffer (Abcam) with mixtures containing RNase in-
hibitor (GenDEPOT, Hanam, Korea) and protease inhibitor 
(GenDEPOT). For chromatin shearing, 20 cycles (170–190 W 
for each cycle) of shearing were performed under cooling con-
ditions with a sonicator. Antibodies were applied to the super-
natant and then incubated overnight at 4°C with a rotator. Af-
ter incubation, 20 μL of MagnaChip protein magnetic beads 
(Millipore, Burlington, MA, USA) was added and reacted on a 
rotator at 4°C for 1 hour. After washing twice with RIP buffer, 
the samples were dissolved with TRIzol reagent or RIPA buffer 
for further studies.
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Methylation-specific PCR (MS-PCR)
Genomic DNA was extracted from AGS cells, as well as paired 
gastric normal and cancer tissues, using a DNeasy Blood & 
Tissue kit (Qiagen, Valencia, CA, USA). An EZ DNA methyla-
tion-gold kit (Zymo Research, Irvine, CA, USA) was used for 
DNA bisulfate transformation. Primers were designed for spe-
cific methylated and unmethylated sites. The primers used for 
qRT-PCR are shown in Supplementary Table 2 (only online).
Chromatin immunoprecipitation (ChIp) assay
Cell lysates were transfected with siCT or siLUCAT1s, followed 
by chromatin shearing utilizing water bath sonication for 30 
cycles under a cooling condition (170–190 W). The fragment-
ed chromatin was isolated with the High-Sensitivity Chip kit 
(ab185913; Abcam) according to the manufacturer’s protocol. 
Then, 5 μg of total chromatin was prepared for ChIp with anti-
H3K27me3 (ab6002; Abcam) and the mock immunoprecipi-
tation (IgG, ab185913; Abcam) at 4°C overnight. After cross-
link reversal and DNA purification, qRT-PCR was performed 
with selected target region primers. The primer sequences for 
qRT-PCR are shown in Supplementary Table 3 (only online).
Statistical analysis
All of the analyzed data for continuous variables are presented 
as a mean±standard error. Categorical variables are presented 
as a number and proportion. Statistical tests included the t-
test, χ2 test, Fisher’s exact test, and ANOVA test. One-way anal-
ysis of variance (ANOVA) was performed with Duncan’s mul-
tiple range test. The expression of LUCAT1 in GC was classified 
as low or high based on the average value of LUCAT1 expres-
sion. The Kaplan-Meier method and log-rank test were used 
for survival analysis. A p value<0.05 was regarded as a statisti-
cally significant difference for group comparisons. All statisti-
cal processes were conducted using the statistical software 
SPSS for Windows (version 18.0; SPSS Inc., Chicago, IL, USA).
Fig. 1. Expression of LUCAT1 is overexpressed in gastric cancer cell lines and tissues. (A) LUCAT1 expression was upregulated in four gastric cancer 
cells (AGS, MKN28, MKN45, and MKN74), compared to normal gastric cells (GES1). (B) LUCAT1 expression was determined in stomach adenocarcinoma 
(STAD) and esophageal adenocarcinoma (ESCA) using GTEx and TCGA data (http://gepia.cancer-pku.cn/detail.php?gene=LUCAT1). (C) LUCAT1 expres-
sion was examined in cancer tissues and adjacent non-tumor tissues (n=100). The expression of LUCAT1 was measured by quantitative real-time PCR 
and calculated by the 2-ΔΔCT method using quantitative real-time PCR. (D) Kaplan-Meier estimates of overall survival in patients with high or low LUCAT1 
expression. p-values were 0.049. All of the data are from three independent experiments. Data are presented as the mean±s.e.m. Asterisk indicates a 
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RESULTS
Expression of LUCAT1 in gastric cancer cell lines and 
tissues 
The expression of LUCAT1 in GC cell lines and gastric tissues 
was analyzed using qRT-PCR. LUCAT1 was expressed at vari-
ous levels in five GC cell lines and normal gastric cell line 
(GES1) (Fig. 1A). Expression of LUCAT1 was higher in MKN28, 
MKN45, MKN74, and AGS than in normal gastric cells (Fig. 
1A). In genotype-tissue expression (GTEx) and Cancer Ge-
nome Atlas (TCGA) datasets, LUCAT1 was significantly upreg-
ulated in both esophageal adenocarcinoma and GC (STAD) 
(Fig. 1B). We validated the expression of LUCAT1 in GC speci-
mens of 100 patients who underwent surgery due to GC. Ex-
pression of LUCAT1 was significantly higher in GC tissues 
than in adjacent non-tumor tissues (p<0.001) (Fig. 1C). 
Expression of LUCAT1 and the clinicopathologic 
characteristics of gastric cancer 
Clinicopathological features of the patients are summarized 
in Table 1. The patients’ mean age was 65 years, and men ac-
counted for 81% of all patients. The overall survival rate in the 
high LUCAT1 expression group tended to be lower than that in 
the low LUCAT1 expression group (p=0.049) (Fig. 1D). When 
we analyzed disease-free survival in our patients (p=0.13) and 
the TCGA cohort patients (p=0.25) based on the expression 
level of LUCAT1, LUCAT1 did not affect disease-free survival 
in GC patients (data not shown). 
Downregulation of LUCAT1 suppresses 
the proliferation of gastric cancer cells and induces 
apoptosis
For further experiments, we selected AGS, MKN28, and MKN74 
cells, which express LUCAT1 at relatively high levels. To evalu-
ate the effects of LUCAT1 on the proliferation of GC cell lines by 
Table 1. Relationships between LUCAT1 Expression and Clinicopathological Features in 100 Gastric Cancer Patients
Clinicopathological variables Number in each group
LUCAT1 expression‡
p value
Low (<0.0438), n (%) High (≥0.0438), n (%)
All cases 100 37 63
Age (yr) 0.037 
<65 56 26 (70.3) 30 (47.6)
≥65 44 11 (29.7) 33 (52.4)
Sex 0.522 
Male 62 21 (56.8) 41 (65.1)
Female 38 16 (43.2) 22 (34.9)
HP 0.449 
Positive 26 8 (21.6) 18 (28.6)
Negative 14 5 (13.5) 9 (14.3)
Location* 0.225 
Upper third 12 5 (13.5) 7 (11.1)
Middle third 38 17 (45.9) 21 (33.3)
Lower third 50 15 (40.5) 35 (55.6)
T stage 0.380 
T1 16 4 (10.8) 12 (19)
T2 8 4 (10.8) 4 (6.3)
T3 27 9 (24.3) 18 (28.6)
T4 49 20 (54.1) 29 (46)
Depth of tumor invasion 0.810 
T1/T2 24 8 (21.6) 16 (25.4)
T3/T4 76 29 (78.4) 47 (74.6)
Lymph node metastasis 0.167 
Absent 28 7 (18.9) 21 (33.3)
Present 72 30 (81.1) 42 (66.7)
N stage 0.355 
N0 28 7 (18.9) 21 (33.3)
N1 17 9 (24.3) 8 (12.7)
N2 26 9 (24.3) 17 (27.0)
N3 29 12 (32.4) 17 (27.0)
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MTS assay, GC cells were incubated with siRNAs for LUCAT1 
and pcDNA-LUCAT1. After treatment of AGS, MKN28, and 
MKN74 cells with 50 μM siLUCAT1, there was about a 50% 
decline in LUCAT1 expression, compared to cells transfected 
with control siRNA (siCT) (Fig. 2A). Treatment of cells with 
100 μM siLUCAT1 did not result in a substantially greater de-
cline in LUCAT1, compared to using 50 μM siLUCAT1, in AGS 
and MKN 74 cells. Therefore, further experiments were con-
ducted at an siLUCAT1 concentration of 50 μM. pcDNA-LUC-
AT1 induced overexpression of LUCAT1 by about 40-fold, com-
pared to pcDNA vector alone, in three different GC cell lines 
(Fig. 2B). Following transfection of siRNAs, transfection with 
both siLUCAT1_1 and siLUCAT1_2 significantly decreased 
AGS, MKN28, and MKN74 cell viability, compared to siCT. Res-
toration of LUCAT1 expression by pcDNA-LUCAT1 transfec-
tion in siLUCAT1-transfected cells significantly rescued cell 
proliferation in these cells (Fig. 2C). 
Next, we performed PI/Annexin V staining and flow cytom-
etry to evaluate the incidence of apoptotic cell death after al-
teration of LUCAT1. AGS, MKN28, and MKN74 cells transfect-
ed with siLUCAT1s showed a significant increase in early-to-
late apoptotic ratio, compared to cells transfected with siCT 
(Fig. 2D). Poly (ADP-ribose) polymerase was cleaved by trans-
fection of siLUCAT1 in AGS, MKN28, and MKN74 cells (Fig. 2E). 
siLUCATs increased the expression of Bax and suppressed the 
expression of Bcl-xl in three different cell lines (Fig. 2E). These 
changes were reversed by overexpression LUCAT1 upon 
transfection of pcDNA-LUCAT1. 
siLUCAT1 suppresses invasion and migration in 
gastric cancer cells
Transfection of AGS, MKN28, and MKN74 cells with two dif-
ferent LUCAT1s significantly reduced invasion ability in Matri-
gel invasion assay (Fig. 3A). In wound-healing assay, siLUC-
AT1s repressed the migration ability of three GC cell lines, 
compared with siCT, which was consistent with the invasion 
assay results (Fig. 3B). These reductions in invasion and migra-
tion were reversed by overexpression of LUCAT1 upon trans-
Table 1. Relationships between LUCAT1 Expression and Clinicopathological Features in 100 Gastric Cancer Patients (continued)
Clinicopathological variables Number in each group
LUCAT1 expression‡
p value
Low (<0.0438), n (%) High (≥0.0438), n (%)
Lymphovascular invasion 0.383 
Absent 33 10 (27.0) 23 (36.5)
Present 67 27 (73.0) 40 (63.5)
Stage† 0.837 
I, II 42 15 (40.5) 27 (42.9)
III 58 22 (59.5) 36 (57.1)
Lauren’s classification 0.175 
Intestinal 49 15 (40.5) 34 (54)
Diffuse 43 18 (48.6) 25 (39.7)
Mixed 8 4 (10.8) 4 (6.3)
Differentiation (Diff. vs. Undiff.) 0.532 
Well to moderate 42 14 (37.8) 28 (45.2)
PD to SRC 57 23 (62.2) 34 (54.8)
Serum CEA value 0.799 
≤5 80 29 (78.4) 51 (81.0)
>5 20 8 (21.6) 12 (19.0)
Serum CA19-9 value 0.667 
≤37 94 34 (91.9) 60 (95.2)
>37 6 3 (8.1) 3 (4.8)
Preop chemotherapy 1.000 
No 96 36 (97.3) 60 (95.2)
Yes 4 1 (2.7) 3 (4.8)
Adjuvant chemotherapy 0.059 
No 43 11 (29.7) 32 (50.8)
Yes 57 26 (70.3) 31 (49.2)
HP, Helicobacter pylori; PD, poorly differentiated adenocarcinoma; SRC, signet ring cell carcinoma; CEA, carcinoembryonic antigen; CA19-9, carbohydrate anti-
gen 19-9.
*Location was classified according to the American Joint Cancer Committee on Cancer staging system, †Stage was classified according to the 7th edition of the 
American Joint Cancer Committee on Cancer staging system, ‡Patients were classified into two groups according to average LUCAT1 expression with a cut-off 
value of 0.0488.
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fection with pcDNA-LUCAT1 (Fig. 3A and B).
Next, we performed soft agar colony formation assay to as-
sess in vitro cellular anchorage-independent growth. The 
number and size of forming colonies declined notably in AGS 
cells transfected with siLUCAT1s, compared to cells transfect-
ed with siCT (Fig. 3C). Next, we evaluated differential expres-
Fig. 2. Knockdown of LUCAT1 expression inhibits cell proliferation and induces apoptosis in gastric cancer cells. Expression of LUCAT1 was mea-
sured by qRT-PCR in AGS, MKN28, and MKN74 cells transfected with (A) siRNAs and (B) overexpression of LUCAT1 (pcDNA-LUCAT1). (C) Cell prolif-
eration was detected by MTS assay. (D) AGS, MKN28, and MKN74 cells were transfected with siCT or siLUCAT1s, followed by apoptosis assay using 
PI/Annexin-V staining. (E) Apoptotic markers were detected in transfected AGS, MKN28, and MKN74 cells. All of the data are from three independent 




























0     24    48     72 0     24    48     72 0     24    48     72 







































































* * * * * * * *** **
  siCT        siLUCAT1_1 50 uM
  siLUCAT1_1 100 uM       siLUCAT1_2 50 uM





  Control   siCT
  si1   si2
  si1+pcDNA
  si2+pcDNA
  Control   siCT
  si1   si2
  si1+pcDNA
  si2+pcDNA
  Control   siCT
  si1   si2
  si1+pcDNA
  si2+pcDNA




   
   
   
   
   




   
   
   
   
   




** ** ** **
**
 siCT + - - - - + - - - - + - - - -
 siLUCAT1_1 - + - + - - + - + - - + - + -
 siLUCAT1_2 - - + - + - - + - + - - + - +

















Epigenetic Regulation of CXXC4 and SFRP2 by LUCAT1
https://doi.org/10.3349/ymj.2020.61.11.923
sion of EMT markers using Western blot. The expression of 
the mesenchymal markers Snail, N-cadherin, and vimentin 
were reduced, whereas that of E-cadherin was increased after 
transfection of cells with siLUCAT1s, compared to siCT, al-
though these were revered by transfection of pcDNA-LUCAT1 
(Fig. 3D). Taken together, these finding indicated that LUCAT1 
affects cell migration and invasion, which are involved in car-
cinogenesis. 
LUCAT1 regulates methylation of CXXC4 and SFRP2 
through the EZH2/Wnt/β-catenin pathway
In our previous study, microarray analysis revealed 770 cancer-
related genes in ESCC after transfection with siLUCAT1.27 Us-
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AGS                                       MKN28                                MKN74
Fig. 3. siLUCAT1s suppress the cell migration and invasion of AGS, MKN28, and MKN74 cells. (A) Invasion assays and (B) wound healing assays were 
performed, followed by siCT or siLUCAT1s. At 48 hours after transfection of siLUCAT1s, pcDNA-LUCAT1 was transfected into cells, and then migration 
and invasion was observed by microscopy. Bar graph shows the percentage of wound closures and the number of invading cells. (C) Soft agar colo-
ny formation was carried out during the knockdown of LUCAT1 in AGS cells. (D) EMT markers were performed by immunoblotting transfected AGS, 
MKN28, and MKN74 cells. All of the data are from three independent experiments. Data are presented as the mean±s.e.m. Asterisk indicates a sta-
tistically significant difference compared to scrambled control. *p≤0.05, **p≤0.01.
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ing on tumor suppressor genes that have already been reported 
to be reduced due to methylation in GC. In doing so, we con-
firmed that mRNA expression of tumor suppressor genes, 
such as DKK3, PCDH10, ZNF331, CXXC4, and SFRP2, were 
increased by siLUCAT1 more than twice that of siCT (data not 
shown), and we decided to analyze CXXC4 and SFRP2 for fur-
ther experiments: CXXC4 and SFRP2 have been reported to 
be downstream targets of EZH2/Wnt/β-catenin in GC.34,35 We 
assessed the mRNA levels and methylation status of the can-
didate tumor suppressor genes, CXXC4 and SFRP2, and found 
that the methylation status of these two genes was significant-
ly elevated by siLUCAT1 transfection, compared with siCT 
Fig. 4. LUCAT1 controls the methylation of CXXC4 and SFRP2 through interactions with EZH2 and H3K27me3. (A) The expression of CXXC4 and SFRP2 
was detected by qRT-PCR and MS-PCR in AGS cells treated with siCT or siLUCAT1s. (B) The methylation status of CXXC4 and SFRP2 was estimated in 
five cancer tissues and adjacent non-tumor tissues via MS-PCR. (C) After treatment with siCT or siLUCAT1s, H3K27me3 and H3K9me3 antigens were 
detected by immunoblotting. (D) AGS cell lysates were immunoprecipitated with anti-EZH2 antibody, and the interaction between EZH2 and LUCAT1 
was confirmed through RIP analysis. (E) The translational levels of EZH2 and its downstream signals, Wnt and β-catenin, were measured by immunob-
lotting. (F) Immunoblotting was performed using AGS cells transfected with siCT or siEZH2 and with both siEZH2 and siLUCAT1 (double-knockdown). (G) 
H3K27me3 enrichment on CXXC4 and SFRP2 genes in ChIP assay in siCT- or siLUCAT1s-transfected AGS cells by qRT-PCR at respective potential regu-
latory regions. All of the data are from three independent experiments. Data are presented as the mean±s.e.m. Asterisk indicates a statistically significant 
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transfection, in AGS cells (Fig. 4A). This was confirmed in five 
paired adjacent non-tumor tissues and cancer tissues by MS-
PCR (Fig. 4B). Therefore, our findings confirmed that LUCAT1 
is involved in the methylation of tumor suppressor genes in 
GC. The expressions of H3K9me3 and H3K27me3 were re-
duced by treatment with siLUCAT1s, thus this reduction of 
histone markers was correlated with methylation of tumor 
suppressor genes (Fig. 4C). 
Next, we analyzed the effects of LUCAT1 on EZH2, which is 
the major chromatin repressive modification marker that in-
teracts with H3K27me3. LUCAT1 and EZH2 interaction was 
established by RIP assay; LUCAT1 was abundant in the anti-
EZH2 RIP fraction, compared to IgG fraction (Fig. 4D). EZH2, 
acting as an upstream regulator of Wnt/β-catenin, could sup-
press WNT expression and induce H3K27 methylation, lead-
ing to inactivation of the Wnt/β-catenin pathway36; however, 
no previous association with LUCAT1 has been identified. To 
confirm the relationship between LUCAT1 and EZH2/Wnt/
β-catenin, we performed Western blot assay and found that 
the protein levels of EZH2, Wnt, and β-catenin were signifi-
cantly increased after LUCAT1 knockdown, while overexpres-
sion of LUCAT1 almost fully reversed the changes by LUCAT1 
knockdown (Fig. 4E). The expressions of CXXC4 and SFRP2, 
which are targets of EZH2/Wnt/β-catenin, also changed un-
der the same conditions (Fig. 4E). Next, we introduced siEZH2 
and siLUCAT1 into cells to perform a double-knockout of EZH2 
and LUCAT1. Double knockdown of EZH2 and LUCAT1 further 
decreased levels of EZH2, Wnt, and β-catenin, compared to 
knockdown of EZH2 or LUCAT1 alone (Fig. 4F). 
To confirm interactions among H3K27me3, LUCAT1, CXXX4, 
and SFRP2, we performed ChIP assays to assess signals of 
H3K27me3 in CXXC4 and SFRP2 genomic regions according 
to the presence or absence of LUCAT1, and found a signifi-
cant decline in H3K27me3 signals at specific sites in the genes 
(indicated in primers 2,5 for CXXC4 and primers 1,2 for SFRP2) 
upon knockdown of LUCAT1 cells (Fig. 4G). This result indi-
cated that LUCAT1 is involved in the binding of H3K27me3 to 
CXXC4 and SFRP2 genes. 
DISCUSSION
Among the various mechanisms involved in the development 
and progression of cancer, lncRNA has recently been shown 
to play a significant role therein. We previously reported that 
LUCAT1 promotes ESCC by inhibiting the expression of tumor 
suppressor genes. Specifically, we found that LUCAT1 regu-
lates the stability of DNMT1, which is likely to result in broad 
alterations in DNA methylation in various cancers.27 In the 
present study, LUCAT1 was upregulated in GC, compared to 
adjacent non-tumor tissue. Transfecting GC cells with siRNAs 
against LUCAT1 reduced the proliferation, migration, invasion, 
and the colony formation ability of the GC cells. Transfection 
of cells with pcDNA-LUCAT1 rescued this inhibition. Knock-
down of LUCAT1 reduced the methylation status of CXXC4 and 
SFRP2 and the expression of H3K27me3 by targeting EZH2, 
which leads to activation of the Wnt/β-catenin signaling path-
way. Moreover, silencing of LUCAT1 inhibited the binding of 
EZH2 to CXXC4, H3K27me3, and SFRP2. Our results indicate 
that LUCAT1 is involved in epigenetic repression of tumor sup-
pressor genes in GC.
Since LUCAT1 was first introduced in 2013 under the name 
of smoke and cancer-associated lncRNA-1 (SCAL1), it has 
been shown to be expressed in serous ovarian cancer, clear 
cell renal cell carcinoma, colorectal cancer, bladder cancer, 
osteosarcoma, glioma, esophageal, head and neck squamous 
cell carcinoma, prostate, hepatocellular carcinoma, triple nega-
tive breast cancer, and cervical cancer. Chi, et al.37 reported that 
LUCAT1 promotes GC by regulating the miR-134-5p/YWHAZ 
axis. Here, we found that LUCAT1 expression was higher in GC 
tissue than in adjacent non-tumor tissue. When we simply 
compared the relative increases in LUCAT1 in GC and ESCC 
in relation to overall survival in our current and previous stud-
ies, we inferred that LUCAT1 may be a better target for squa-
mous cell carcinoma than adenocarcinoma due to the large 
increase in LUCAT1 expression in ESCC, compared to GC. To 
confirm this, however, additional GC and ESCC cohorts are 
needed, and we are now doing this project. 
LUCAT1 has been shown to be involved in GC carcinogen-
esis via methylated tumor suppressor genes, such as CXXC4 
and SFPR2. CXXC4 was reported to be a novel tumor suppres-
sor in GC.34,38 CXXC4 acts as a negative regulator of the Wnt 
signaling pathway and contributes to tumor suppression. Alter-
ation of the methylation status of CXXC4 or mutation of this 
gene have been reported in GC.37 We examined the methyla-
tion status of CXXC4 and SFRP2 in non-tumor and cancer tis-
sues from five patients, and found that these two genes were 
more highly methylated in cancer tissue than in non-tumor 
tissue. We also found that siLUCAT1 reduced methylation of 
CXXC4 and SFRP2 in GC cells.
EZH2 has been reported to induce aberrant activation of 
WNT signaling by downregulating CXXC4 expression in GC.34 
Additionally, recent studies have shown that lncRNA can im-
pact methylation status by binding with EZH2 in various can-
cers.39,40 siLUCAT1 reduced the expression of EZH2 and induced 
the expression of CXXC4, while overexpression of LUCAT1 re-
stored the expression levels of EZH2 and CXXC4 in Western 
blot experiments. This suggests that LUCAT1 regulates the ex-
pression of E-cadherin, N-cadherin, and vimentin, which are 
all markers of WNT and EMT signaling. The expression of 
Wnt/β-catenin was more prominently reduced when siEZH2 
and siLUCAT1 were administered simultaneously, compared 
to when only siEZH2 was administered. These results suggest 
that, in addition to EZH2, LUCAT1 is involved in Wnt/β-catenin 
signaling, and this should be further investigated. 
In this study, we demonstrated that EZH2 directly binds 
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with LUCAT1 in RIP assay, and the mechanism by which LU-
CAT1 enhances EZH2 can be predicted from our previous ex-
periments.27 Our results indicated that LUCAT1 regulates the 
ubiquitination of DNMT1 mediated by the E3 ubiquitin-pro-
tein ligase UHRF1. Accordingly, decreasing protein levels of 
EZH2 by siLUCAT1 in our present result is expected to be a 
function of ubiquitination in EZH2. Additional studies should 
be performed to discover the relationship between EZH2 and 
LUCAT1.
Furthermore, siLUCAT1 reduced the expression of H3K-
27me3 in GC cell lines. In ChIP analysis, siLUCAT1 selectively 
inhibited the binding of H3K27me3 to CpG islands of CXXC4 
and SFRP2 genes. This implies that LUCAT1 is involved in the 
EZH2-mediated repression of H3K27me3, as well as in meth-
ylation of the tumor suppressor genes CXXC4 and SFRP2.
In conclusion, LUCAT1 inhibits CXXC4 expression through 
induction of EZH2 expression, H3K27me3-mediated epigene-
tic regulation, and methylation of CXXC4 and SFRP2. LUCAT1 
can thereby activate the WNT pathway and play a role in GC 
development. Our study proposes a new mechanism by which 
LUCAT1 interacts with a key pathway in GC development. 
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